TCTMD - tctmd.com
WEBGiven the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart ...
Blood Pressure Insights in COVID-19: Watch for Drops and RAAS …
WEBSep 10, 2020 · Here, Baher Al-Abbasi, MD (University of Miami/JFK Medical Center, Atlantis, FL), and colleagues noted increased in-hospital mortality in 172 COVID-19 patients taking ACE inhibitors or ARBs compared with those not taking the drugs (33% vs 13%; P = 0.003), as well as increased likelihood of admission to the …
St. Jude Medical Furthers the Company’s Legacy of Heart Valve ...
WEBMay 16, 2016 · ST. PAUL, Minn., St. Jude Medical, Inc., a global medical device company, today announced the U.S. launch of the company’s most advanced tissue valve — the Trifecta™ valve with Glide™ Technology (GT) — for the treatment of patients diagnosed with unhealthy, damaged or malfunctioning aortic heart valves.Designed with feedback from a cohort of international physicians, the Trifecta GT ...
FDA Approves Shockwave Intravascular Lithotripsy for Calcified ...
WEBFeb 16, 2021 · (UPDATED) The US Food and Drug Administration has cleared the Shockwave intravascular lithotripsy (IVL) system for the treatment of severely calcified coronary artery plaques. The device uses a balloon to deliver sonic pressure waves that can pass through soft arterial tissue to “preferentially …
The Lutonix® 035 Drug Coated Balloon is the First and Only
WEBOct 10, 2014 · MURRAY HILL, N.J.-- C. R. Bard, Inc. today announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix® 035 Drug Coated Balloon (DCB) Catheter for percutaneous transluminal angioplasty (PTA), after pre-dilatation, for the treatment of de novo or restenotic lesions up to 150mm in length in native vascular disease of the superficial femoral or popliteal arteries with reference ...
Thoratec Announces Start Of Heartmate III™ U.S. Clinical Trial
WEBSep 9, 2014 · The HeartMate III U.S. clinical trial is a randomized non-inferiority study comparing HeartMate III with HeartMate II®™ and includes a primary endpoint of survival free of device replacement and debilitating stroke. The trial began enrollment in a safety phase under conditional approval from the FDA for 30 patients at five sites.
Colchicine Cost-effective in Canada, and Even in the US: COLCOT
WEBMar 28, 2020 · Colchicine costs 26 cents per pill in Canada, as compared to $4 to $6 in the United States, Samuel noted. “We talk a lot in the cardiovascular community about drugs that are both effective and that we can afford to pay for. And these data are obviously exceptional in that regard,” said Paul Ridker, MD (Brigham and Women’s Hospital, Boston ...
TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without …
WEBSep 26, 2019 · SAN FRANCISCO, CA (UPDATED)—Dropping aspirin after 3 months of dual antiplatelet therapy (DAPT) with ticagrelor (Brilinta, AstraZeneca) following PCI among high-risk patients is associated with lower rates of bleeding but no increased risk of death, MI, or stroke, according to results of the double-blind, placebo-controlled TWILIGHT trial.
Loading Dose Smooths Switch From Ticagrelor to Clopidogrel …
WEBMar 20, 2018 · By Yael L. Maxwell. ORLANDO, FL—Patients with coronary artery disease who need to switch from ticagrelor to clopidogrel after PCI should receive a loading dose of 600 mg clopidogrel between 12 and 24 hours following ticagrelor discontinuation, according to results from a randomized, pharmacodynamic study. Findings from the …
Is Tenecteplase Ready for Prime Time in Acute Stroke?
WEBMar 19, 2021 · That includes single-bolus administration, which avoids the hour-long infusion required for alteplase and may speed the transfer of patients who need thrombectomy to another center. “Tenecteplase is ready for prime time,” Saver said. But Patrick Lyden, MD (University of Southern California, Los Angeles), countered that the head-to-head ...
Skip to content